Farxiga Lawsuit | 2026 Latest Updates

AstraZeneca makes the diabetes drug Farxiga (dapagliflozin). The drug is also sold with metformin as Xigduo XR. Product-liability lawsuits claim Farxiga and Xigduo XR caused diabetic ketoacidosis, acute kidney injury, or Fournier’s gangrene. Fournier’s gangrene is a rare genital infection. Plaintiffs claim AstraZeneca failed to test the drug enough and failed to warn patients and doctors about the risks. A federal MDL once combined Farxiga lawsuits in New York, but it closed in 2020. Claims now move forward one by one in Delaware State Court. AstraZeneca has disclosed a settlement in principle, for an undisclosed amount, in one case set for trial. The earliest remaining Delaware trial is now set for September 2026.

Latest Farxiga Lawsuit Updates

February 10, 2026: AstraZeneca Discloses a Farxiga Settlement in Principle

AstraZeneca‘s Annual Report and Form 20-F Information 2025 discloses a settlement in principle for a non-material, undisclosed amount[1]. The settlement resolves the one case that had been scheduled for trial in March 2026. All remaining Farxiga and Xigduo XR product-liability claims are filed individually in Delaware State Court, and their earliest trial is now scheduled for September 2026.

July 23, 2020: MDL No. 2776 Was Terminated

MDL No. 2776 was terminated, per the court’s docket[2], ending centralized pretrial proceedings in New York federal court. The MDL had combined Farxiga and Xigduo XR lawsuits alleging diabetic ketoacidosis, kidney injury, and Fournier’s gangrene. Individual product-liability claims now proceed separately in Delaware State Court. AstraZeneca and originally Bristol-Myers Squibb, Farxiga’s co-developer, were both named as defendants in the litigation.

April 6, 2017: A Federal Panel Centralized Farxiga Lawsuits into MDL No. 2776

The JPML centralized eighteen federal Farxiga and Xigduo XR lawsuits into MDL No. 2776[3]. The cases moved to the Southern District of New York. Judge Lorna G. Schofield took over. It was her first MDL. The panel found the cases shared common questions. These covered how the drugs were tested, labeled, and marketed. Centralizing them would save time and avoid conflicting rulings.

December 4, 2015: FDA Added Ketoacidosis and UTI Warnings to SGLT2 Labels

The FDA added new warnings to SGLT2 inhibitor labels, the drug class that includes Farxiga[4]. The warnings covered ketoacidosis and serious urinary tract infections. They followed a review of adverse-event reports filed from March 2013 through May 2015. The review’s ketoacidosis case count for the drug class matches the count in Reported Injuries or Damages; dapagliflozin, the active ingredient in Farxiga and Xigduo XR, was involved in several cases. All patients needed hospital or emergency treatment.

What Is Farxiga?

Farxiga is the brand name for dapagliflozin. It is a sodium-glucose cotransporter 2 inhibitor made by AstraZeneca, per its FDA-approved label[5]. It lowers blood sugar. It does this by causing the kidneys to remove excess sugar through urine. The FDA first approved Farxiga in 2014, for adults with type 2 diabetes. Xigduo XR combines dapagliflozin with metformin in one tablet. AstraZeneca has since expanded Farxiga’s approved uses. These now include reducing heart failure and chronic kidney disease risk.

Who May Be Affected?

People who took Farxiga or Xigduo XR make up the population these lawsuits describe. Many were later diagnosed with diabetic ketoacidosis, acute kidney injury, or Fournier’s gangrene. Regulators have found these events in two patient groups, those using the drugs as approved for type 2 diabetes and those using them off-label for type 1 diabetes. The FDA’s label warns against that off-label use, citing ketoacidosis risk. Relevant circumstances include hospitalization for diabetic ketoacidosis or acute kidney injury, and surgery or hospitalization for Fournier’s gangrene, after taking Farxiga or Xigduo XR. New symptoms after starting Farxiga, Xigduo XR, or a higher dose also count. The same FDA review found a median onset of 43 days, ranging from one day to one year. AstraZeneca has already disclosed a settlement in principle. It covers one such case. Confirming whether a specific case qualifies takes an individual legal review of the medical and prescription records.

Reported Injuries or Damages

The lawsuits center on one claim: Farxiga and Xigduo XR led to diabetic ketoacidosis, kidney injury, or Fournier’s gangrene. That infection is severe and can turn life-threatening. The FDA’s own reviews of adverse-event reports do not prove the drug caused any single case. But they show how often these events reached the agency. FDA reviewed reports from March 2013 to May 2015. It tallied seventy-three ketoacidosis cases across the SGLT2 class. Dapagliflozin was involved in twenty-one of them. A later FDA review covered March 2013 through October 2015. It counted 101 acute kidney injury cases. Seventy-three were tied to canagliflozin, and twenty-eight to dapagliflozin[6]. Farxiga’s own label separately warns about Fournier’s gangrene. It has been reported in patients taking the drug. Outcomes have included hospitalization, multiple surgeries, and death. The ATTEMPT trial, published in Nature Medicine, tested Farxiga in ninety-eight adolescents who had type 1 diabetes. Researchers closely monitored participants, and just one mild ketoacidosis incident turned up during the trial[7]. A related SGLT2 inhibitor, canagliflozin, is the subject of its own Invokana lawsuit, filed separately from the Farxiga and Xigduo XR litigation.

Evidence to Preserve

These records matter most for a Farxiga or Xigduo XR product-liability claim, before they are lost, discarded, or otherwise become hard to find:

• Pharmacy and prescription records showing when Farxiga or Xigduo XR was prescribed and for how long it was taken
• Medical records documenting the diagnosis of diabetic ketoacidosis, acute kidney injury, or Fournier’s gangrene, along with the treatment given
• Hospital admission, emergency room, and surgical records from the treatment of the diagnosed condition
• Photographs showing any visible injury, surgical site, or hospital stay related to the diagnosis
• Correspondence with the prescribing doctor about the diagnosis and any discussion of the drug as a possible cause
• Insurance claims, billing statements, and explanation-of-benefits records related to the hospitalization or treatment
• The product packaging, container, or pharmacy label, if it was kept after the prescription was filled

Beyond Farxiga and Xigduo XR claims, the same evidence types apply broadly across other dangerous drug lawsuits involving similar prescription medications.

Filing Deadlines

Deadlines for filing a Farxiga or Xigduo XR claim come from state law. They depend on where the person lives. The clock often starts at diagnosis, for diabetic ketoacidosis, kidney injury, or Fournier’s gangrene. Some states instead use the date of first use. Missing a filing deadline can end a claim, even with strong medical evidence. Anyone weighing a Farxiga or Xigduo XR claim should speak with a lawyer soon after the diagnosis.

Potential Compensation

AstraZeneca’s newest annual report names no dollar figure for that settlement. None can be stated on this page with real confidence. In lawsuits like this, plaintiffs may seek several kinds of damages. These can include past and future medical expenses, lost income, and pain and suffering. What applies depends on the facts. Compensation amounts vary by case. Past results do not guarantee future outcomes. A lawyer reviewing the Farxiga or Xigduo XR records can explain which potential compensation category might fit a specific claim.

Frequently Asked Questions

Has Farxiga Been Recalled?

No, Farxiga has not been recalled. No regulator has issued a recall for Farxiga or Xigduo XR. Both drugs remain FDA-approved and on the market. Regulators handled the ketoacidosis, kidney, and Fournier’s gangrene concerns through label-warning updates instead.

What Are the Symptoms of Fournier’s Gangrene?

The symptoms of Fournier’s gangrene include sudden pain, swelling, and redness in the genital or perineal area. Fever, chills, and malaise are also common. The infection can progress rapidly. Anyone with these symptoms after taking Farxiga should seek emergency care immediately.

What Does the ATTEMPT Trial Say About Farxiga’s Safety?

The ATTEMPT trial studied Farxiga’s safety in ninety-eight adolescents with type 1 diabetes. It was published in Nature Medicine. Farxiga lowered A1c by 0.47% and cut weight by 2.8 kilograms on average. Only one mild ketoacidosis event occurred, under close monitoring.

Where Were the Original MDL Lawsuits Filed?

The original MDL lawsuits were filed across six federal districts. Thirteen of the eighteen cases were already pending in New York’s Southern District. One each was pending in Alabama, Illinois, Louisiana, Mississippi, and Pennsylvania federal courts. The JPML then centralized them.

Did Any Original MDL Case Also Name Other SGLT2 Drugs?

Yes, one original MDL case did name other SGLT2 drugs. An Eastern District of Pennsylvania action listed Invokana (canagliflozin) alongside Farxiga and Xigduo XR as a so-called combination case. The JPML’s transfer order sets that filing apart from the other seventeen single-drug actions.

Are Other SGLT2 Inhibitors Facing Similar Lawsuits?

Yes, other SGLT2 inhibitors face similar lawsuits. Canagliflozin, sold as Invokana, has its own separate federal MDL, No. 2750. It was formed for claims raising the same kidney-injury and ketoacidosis allegations as the Farxiga litigation.

References

1. https://www.sec.gov/Archives/edgar/data/901832/000110465926019110/tm261135d3_ex99-1.pdf
2. https://www.courtlistener.com/docket/6065928/in-re-farxiga-dapagliflozin-products-liability-litigation/
3. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-2776-Initial_Transfer-03-17.pdf
4. https://www.fda.gov/files/drugs/published/FDA-revises-labels-of-SGLT2-inhibitors-for-diabetes-to-include-warnings-about-too-much-acid-in-the-blood-and-serious-urinary-tract-infections.pdf
5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s026lbl.pdf
6. https://web.archive.org/web/20190208025129/https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm
7. https://web.archive.org/web/20250910235713/https://www.managedhealthcareexecutive.com/view/farxiga-can-be-safely-used-by-adolescents-with-type-1-diabetes